{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:11:52Z","timestamp":1790140312240,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.euros.2024.09.010","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T22:24:11Z","timestamp":1728599051000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Patient-reported Outcome Measures and Decision Regret After Prostate-specific Membrane Antigen\u2013targeted Radioguided Surgery for Oligorecurrent Prostate Cancer"],"prefix":"10.1016","volume":"70","author":[{"given":"Fabian","family":"Falkenbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Mazzucato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Graefen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Steuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Koehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Tennstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Knipper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bud\u00e4us","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2024.09.010_b0005","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2024.09.010_b0010","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eururo.2022.11.002","article-title":"Management of patients with advanced prostate cancer. Part I: intermediate-\/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: report of the Advanced Prostate Cancer Consensus Conference 2022","volume":"83","author":"Gillessen","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2024.09.010_b0015","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/JU.0000000000003890","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part III: salvage therapy after radiotherapy or focal therapy, pelvic nodal recurrence and oligometastasis, and future directions","volume":"211","author":"Morgan","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2024.09.010_b0020","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.euf.2018.02.015","article-title":"Standard of care versus metastases-directed therapy for PET-detected nodal oligorecurrent prostate cancer following multimodality treatment: a multi-institutional case-control study","volume":"5","author":"Steuber","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euros.2024.09.010_b0025","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.eururo.2019.07.009","article-title":"Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer: a multi-institutional analysis comparing the outcome and toxicity of stereotactic body radiotherapy and elective nodal radiotherapy","volume":"76","author":"De Bleser","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2024.09.010_b0030","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2024.09.010_b0035","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.euo.2023.02.010","article-title":"Predictors of recurrence after metastasis-directed therapy in oligorecurrent prostate cancer following radical prostatectomy","volume":"6","author":"Milenkovic","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euros.2024.09.010_b0040","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/pros.23967","article-title":"Optimizing the role of androgen deprivation therapy in advanced prostate cancer: challenges beyond the guidelines","volume":"80","author":"Shore","year":"2020","journal-title":"Prostate"},{"key":"10.1016\/j.euros.2024.09.010_b0045","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2024.09.010_b0050","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(17)30426-6","article-title":"Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01\u201303 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial","volume":"18","author":"Duchesne","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2024.09.010_b0055","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300251","article-title":"Enzalutamide and quality of life in biochemically recurrent prostate cancer","volume":"2","author":"Freedland","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.euros.2024.09.010_b0060","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S1470-2045(18)30898-2","article-title":"Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial","volume":"20","author":"Tombal","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2024.09.010_b0065","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1111\/j.1743-6109.2010.01902.x","article-title":"ADT Survivorship Working Group. Androgen deprivation therapy for prostate cancer: recommendations to improve patient and partner quality of life","volume":"7","author":"Elliott","year":"2010","journal-title":"J Sex Med"},{"key":"10.1016\/j.euros.2024.09.010_b0070","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2022.05.031","article-title":"Cohort study of oligorecurrent prostate cancer patients: oncological outcomes of patients treated with salvage lymph node dissection via prostate-specific membrane antigen-radioguided surgery","volume":"83","author":"Knipper","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2024.09.010_b0075","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.eururo.2018.03.013","article-title":"(99m)Technetium-based prostate-specific membrane antigen-radioguided surgery in recurrent prostate cancer","volume":"75","author":"Maurer","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2024.09.010_b0080","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.eururo.2022.03.002","article-title":"Robot-assisted prostate-specific membrane antigen\u2013radioguided salvage surgery in recurrent prostate cancer using a DROP-IN gamma probe: the first prospective feasibility study","volume":"82","author":"de Barros","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2024.09.010_b0085","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0895-4356(98)00109-7","article-title":"Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment","volume":"51","author":"Gandek","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.euros.2024.09.010_b0090","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","article-title":"A 12-item Short-Form HEALTH SURVEY: construction of scales and preliminary tests of reliability and validity","volume":"34","author":"Ware","year":"1996","journal-title":"Med Care"},{"key":"10.1016\/j.euros.2024.09.010_b0095","unstructured":"Ware JE, Kosinski M, Keller SD. SF-12: How to score the SF-12 physical and mental health summary scales. ed 2. Boston, MA: The Health Institute, New England Medical Center; 1995."},{"key":"10.1016\/j.euros.2024.09.010_b0100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.urology.2014.08.044","article-title":"Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form","volume":"85","author":"Skolarus","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.euros.2024.09.010_b0105","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/0272989X03256005","article-title":"Validation of a decision regret scale","volume":"23","author":"Brehaut","year":"2003","journal-title":"Med Decis Making"},{"key":"10.1016\/j.euros.2024.09.010_b0110","unstructured":"O\u2019Connor AM. User manual\u2014Decision Regret Scale. The Ottawa Hospital Research Institute; 1996. p. 3."},{"key":"10.1016\/j.euros.2024.09.010_b0115","unstructured":"International Consortium for Health Outcomes Measurement. Patient-centered outcome measures: localized prostate cancer. 2024. https:\/\/www.ichom.org\/patient-centered-outcome-measure\/localized-prostate-cancer\/."},{"key":"10.1016\/j.euros.2024.09.010_b0120","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0090-4295(00)00858-X","article-title":"Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer","volume":"56","author":"Wei","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.euros.2024.09.010_b0125","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1007\/s00120-015-3922-0","article-title":"\u201cExpanded Prostate Cancer Index Composite\u201d (EPIC-26): results of functional treatment in patients with localized prostate cancer","volume":"54","author":"Beyer","year":"2015","journal-title":"Urologe A"},{"key":"10.1016\/j.euros.2024.09.010_b0130","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12955-018-0859-1","article-title":"The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimation","volume":"16","author":"Umbehr","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.euros.2024.09.010_b0135","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing; 2023."},{"key":"10.1016\/j.euros.2024.09.010_b0140","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jama.2017.1652","article-title":"Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer","volume":"317","author":"Chen","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.euros.2024.09.010_b0145","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.eururo.2014.08.074","article-title":"Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry","volume":"68","author":"Punnen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2024.09.010_b0150","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.2011.41.2767","article-title":"Long-term disease-specific functioning among prostate cancer survivors and noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial","volume":"30","author":"Taylor","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2024.09.010_b0155","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/cncr.10219","article-title":"Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma","volume":"94","author":"Pickles","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.euros.2024.09.010_b0160","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.euros.2023.04.005","article-title":"The longitudinal course of prospectively recorded patient-reported outcomes in prostate cancer patients treated with surgery and salvage radiotherapy","volume":"53","author":"Hjelle","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euros.2024.09.010_b0165","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jama.2019.20675","article-title":"Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer","volume":"323","author":"Hoffman","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.euros.2024.09.010_b0170","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/bju.15739","article-title":"Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)","volume":"130","author":"Lane","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2024.09.010_b0175","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11934-019-0924-2","article-title":"Quality of life-focused decision-making for prostate cancer","volume":"20","author":"Shevach","year":"2019","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.euros.2024.09.010_b0180","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1209978","article-title":"Long-term functional outcomes after treatment for localized prostate cancer","volume":"368","author":"Resnick","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2024.09.010_b0185","doi-asserted-by":"crossref","unstructured":"Gartrell BA, Phalguni A, Bajko P, et al. Influential factors impacting treatment decision-making and decision regret in patients with localized or locally advanced prostate cancer: a systematic literature review. Eur Urol Oncol. In press. https:\/\/doi.org\/10.1016\/j.euo.2024.04.016.","DOI":"10.1016\/j.euo.2024.04.016"},{"key":"10.1016\/j.euros.2024.09.010_b0190","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/pon.5362","article-title":"Decision regret in men living with and beyond nonmetastatic prostate cancer in the United Kingdom: a population-based patient-reported outcome study","volume":"29","author":"Wilding","year":"2020","journal-title":"Psychooncology"},{"key":"10.1016\/j.euros.2024.09.010_b0195","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/cncr.29309","article-title":"Treatment decisional regret among men with prostate cancer: racial differences and influential factors in the North Carolina Health Access and Prostate Cancer Treatment Project (HCaP-NC)","volume":"121","author":"Morris","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.euros.2024.09.010_b0200","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.euros.2024.05.003","article-title":"Urinary and sexual impact of robotic radical prostatectomy: reporting of patient-reported outcome measures in the first year after radical prostatectomy in a contemporary multicentre cohort in the United Kingdom","volume":"64","author":"Bridge","year":"2024","journal-title":"Eur Urol Open Sci"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168324010851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168324010851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T22:34:44Z","timestamp":1733006084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168324010851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":40,"alternative-id":["S2666168324010851"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2024.09.010","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported Outcome Measures and Decision Regret After Prostate-specific Membrane Antigen\u2013targeted Radioguided Surgery for Oligorecurrent Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2024.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}